More recently developed monotherapies to treat obesity such as the long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, liraglutide and semaglutide (4), produce more pronounced effects on weight loss relative to previous analogues. This evidence concerns the gene GLP1R and Obesity.